1515
Annons
Elicera Therapeutics' Chief Scientific Officer, Professor Magnus Essand, to present at SWECARNET's Educational Day 2022

Gothenburg, February 24, 2022 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company that develops next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced that the company's Chief Scientific Officer (CSO) and co-founder, Professor Magnus Essand, will present at SWECARNET's Educational Day on April 27[th], 2022.

SWECARNET, Sweden's network for clinical use of CAR T-cells, will hold an Educational Day on April 27[th], 2022, where Elicera's CSO, Professor Magnus Essand, will hold a presentation on the topic: What will reseach bring in the future?

More information and the program can be found here: https://atmpsweden.se/events/swecarnet-utbildningsdag-2022/

Registration can be done here: https://www.eventbrite.com/e/swecarnet-utbildningsdag-biljetter-265001345157

About SWECARNET
SWECARNET is Sweden's network for clinical use of CAR T-cells and was established in 2019 by the SDP5 Swelife-ATMP (https://atmpsweden.se/about-atmp-sweden/finalized-initiatives/about-swelife-atmp/)project of the same name. Coordinated by the Centre for Cell therapy and Allogeneic Stem cell Transplantation (CAST) at Karolinska University Hospital, the network brings together those in Sweden developing, implementing or treating patients with Chimeric antigen receptor T (CAR T) cells (https://en.wikipedia.org/wiki/Chimeric_antigen_receptor_T_cell)

Network partners: Uppsala Universitet, Skånes Universitetssjukhus, Sahlgrenska Universitetssjukhuset, Karolinska Institutet, Karolinska Universitetssjukhuset, Novartis Sverige AB, Celgene AB/BMS, Gilead Science Sweden AB, Jansen-Cilag AB and Läkemedelsindustriföreningen

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1090kr
Prenumerera